CONTROLLED RELEASE KCI TABLET FORMULATIONS

Abstract: In accordance with the present invention, controlled release potassium chloride tablets are prepared from a pharmaceutical composition comprised of potassium chloride particles coated with a membrane of plasticized water swellable/soluble polymer. The coated Potassium chloride particles are blended with pharmaceutical excipients and compressed into tablets.

Description: Controlled Release KCI Tablet Formulations Background of the Invention There is a high incidence of severe potassium deficiency in patients treated simultaneously with diuretics and carbenoxolone. In order to maintain the extracellular and intracellular concentrations of potassium within relatively narrow limits, large doses of potassium are required. These doses are released in the body in a controlled release fashion in order to avoid achieving life-threatening toxicity. The strengths of the most dosage forms available in the market place are 8 and 10 mEq KCI capsules or tablets. Since a 20 mEq KCI capsule formulation (exceeding 2 g in weight) is not feasible, there is a need for a 20 mEq KCI tablet formulation. There is a 20 mEq KCI tablet that is commercially available under the tradename, K-DUR 20, based on KCI granules coated with a coating composition comprising of ethyl cellulose (Ethocel Standard Premium 100 or Ethocel Medium 100 from Dow Chemical) and hydroxypropyl cellulose (Klucel from Hercules) using a fluid bed granulator which is made under U.S. Patent 4,863,743 issued to C. Hsiao and T. Chou of Key Pharmaceuticals, Inc. Summary of the Invention An object of the present invention is to provide a method for manufacturing pharmaceutically elegant KCI tablets having sustained release properties (e.g., releasing not more than 40% in one hr and not less than 80% over 8 hrs when tested in USP Apparatus 2 (Paddles @ 50 rpm) in purified water. Another object is to provide tablets with controlled release characteristics, thereby providing treatments for potassium deficiency in humans while minimizing adverse side effects if possible. Since 20 mEq active is equivalent to almost 1500 mg Kcl, it is difficult to provide this dosage in a single tablet, which can deliver an effective daily dose of potassium without being unduly large for swallowing. A more particular but non-limiting further objective of the invention is to provide tablets of total tablet weight of about 2 g (preferably under 2 g) with acceptable hardness (not less than 10 kP) and friability (not more than 1.5%). US Patent 5,422,122 teaches the art of making a pharmaceutical dosage form by first forming KCI microcapsules by coacervation in a cyclohexane solution of ethylcellulose, overcoating the microcapsules with hydroxypropylcellulose and compressing the resulting microcapsules into 20 mEq KCI tablets This patent is incorporated here in its entirety Microencapsulated KCI granules produced by solvent coacervation of ethylcellulose aie often glassy haid granules with poor compactibihty characteristics. In order to improve the compressibihty/compactibihty of the microcapsules, film coating with a variety of plasticized, pharmaceutically acceptable polymeric materials was attempted Polymeric materials found suitable for improving ethylcellulose coated KCI microcapsules include acacia, alginic acid or its salt, com starch, gelatin, xanthan gum, polyvinylpyrrohdone (PVP), sodium carboxymethylcellulose. methylcellulose, low molecular weight ethylcellulose (EC) and hydroxypropylmethyl cellulose (HPMC) alone or in combination. Different plasticizeis such as tπacetin, tπethyl citrate, dibutyl sebacate, polyethylene glycol of molecular weight ranging from 200 to 8,000, were evaluated alone or in combination These attempts have resulted in pharmaceutically elegant 20mEq KCI capsule-shaped tablets weighing about 2 g (generally less) and having controlled release properties (releasing not more than 40% in one hr and not less than 80% over 8 hrs) when tested in USP Apparatus 2 (Paddles @ 50 rpm) m purified water. Thus, one manifestation of the present invention is an improved 20 mEq KCI controlled release dosage form prepared from a multiplicity of ethylcellulose microencapsulated potassium chloride crystals, which are further coated with a plasticized water swellable/soluble polymer or a blend. These membrane coated granules are capable of being compressed into pharmaceutically elegant, easily swallowable 20 mEq KCI tablets of acceptable hardness and friability Of course other KCI dosages are also within the scope of the invention Another manifestation of the present invention is a method for preparing microencapsulated KCI crystals and a method for preparing a KCL tablet Detailed Description of the Invention A plurality of potassium chloride crystals, preferably from about 20 mesh to about 70 mesh, more preferably from about 30 mesh to about 50 mesh, are coated with two distinct layers. The first layer applied to the crystals is composed of ethylcellulose. Utilization of a high viscosity ethylcellulose such as one with a viscosity of from about 90 to about 1 10 cp, e.g., Ethocel 100 (Dow Chemical Corp.) allows the crystals to retain their diffusion controlling characteristics even after compression into a tablet form. The ethylcellulose may be applied by any suitable technique known in the art, but is preferably applied by coacervation using polyethylene as a phase separator as described in U. S. Patent 5,422,122. If coacervation is used, trace amounts of the phase separator may be present in the first layer, preferably in an amount less than about one percent by weight of the ethylcellulose coated crystals. The ethylcellulose layer is preferably applied to the KCI crystals in an amount of about 8 to about 20 percent, more preferably from about 1 1 to about 15 percent, of the total weight of the uncoated potassium chloride crystals. This first layer controls the release of the potassium chloride over time, total release time being proportionally dependent upon the thickness of ethylcellulose. After application of the ethylcellulose, a drying step should preferably be carried out for such a time period and at such temperatures so that the microencapsulated crystals do not adhere to one another. The resultant ethylcellulose encapsulated potassium chloride microcapsules are preferably of such a size that less than 5% are greater than 20 mesh. A second, discrete layer of at least one hydrophilic (water swellable/soluble) polymer coating, is applied over the first layer of ethylcellulose. Hydrophilic polymer coatings include, but are not necessarily limited to acacia, alginic acid or its salt, corn starch, gelatin, xanthan gum, polyvinylpyrrolidone (PVP), sodium carboxymethylcellulose, methylcellulose, low molecular weight ethylcellulose (Ethocel with a viscosity from about 4 to 20 cps) and hydroxypropylmethyl cellulose (HPMC) such as Methocel E5 or 15. These hydrophilic polymers can be used alone or in combination. In accordance with the invention the hydrophilic polymer layer is plasticized. Suitable plasticizers include triacetin, triethyl citrate, dibutyl sebacate (DBS), polyethylene glycol (PEG) of molecular weight ranging from 200 to 8,000 (e.g., a blend of PEG 400 and PEG 4000). The plasticizers can be used alone or in combination. The plasticizer is typically used in an amount of about 2 to 30% based on the combined weight of the hydrophillic polymer and plasticizer. The amount will vary with the type of plasticizer and the nature of the hydrophillic polymer. For example for HPMC and PEG400 the ratio can vary trom about 70/30 to 90/10 With PVP, DBS or triethyl citrate can be used as the plasticizer in a ratio of 94/6 to 97/3. The plasticized hydrophilic layer is applied by conventional techniques, such as from an aqueous solution using a fluidized bed coater, to the preformed layer of ethylcellulose. The hydrophilic polymer coating layer inclusive of the plasticizer is applied m an amount of about 0.5 to 5% w/w (preferably about 1 to 3% w/w and still more typically 2% w/w) of the weight of the ethylcellulose coated crystals. The hydrophilic polymer does not significantly diffuse into the ethylcellulose, but rather forms a distinct second layer. The first membrane of ethylcellulose coacervated in the absence of any plasticizer can be easily distinguishable from the plasticized polymeric membrane by microscopic/spectroscopic techniques. As this layer is soluble to gastric fluids, the hydrophilic polymer coating dissolves following ingestion of the resultant tablet For all practical purposes, it does not contribute to the controlled release of potassium chloride Rather, the hydrophilic polymer coating is present primarily as a binder material so that a high dosage rate tablet can be formed with a minimal amount of conventional excipients and low compaction pressures to allow minimal disruption of the rate controlling ethylcellulose membrane In addition, this formulation allows the microencapsulated potassium chloride to be dispersed essentially mtact over a wide area, reducing the risk of gastric irritation. After the hydrophilic polymer coating layer is applied, the now twice coated crystals are subjected to a final drying step. The resultant coated potassium chloride microcapsules are preferably of such a size that less than 15%, are greater than 20 mesh. The coated crystals may then be formed into tablets by compression using conventional techniques. Preferably a minimal amount of excipients, no more than about 15% more preferably no more than 12%, and most preferably no more than 7% by weight based on the weight of the final dosage tablet, is added to the coated crystals prior to compression. The term "excipients," as used herein, refers to any additional pharmaceutically acceptable ingredients which may be used in a tablet. These excipients include, but are not limited to, ingredients such as diluents or binders, dismtegrants, wetting agents, and lubricating agents. Representative binders include, but are not limited to, Klucel Registered LF (hydroxypropylcellulose) and Avicel Registered (microcrystallme cellulose). Dismtegrants include, but are not limited to, cornstarch, lactose, mannitol, sucrose, Avicel Registered (microcrystallme cellulose), Pπmogel Registered (sodium carboxymethyl starch, Emcompress Registered (dibasic calcium phosphate dihydrate), Crospovidone Registered (cross linked polyvinyl pyrrolidone), and tricalcium phosphate. Wetting agents include, but are not limited to sodium lauryl sulfate. Lubricating agents include, but are not limited to stearates (e.g. magnesium, calcium, and sodium), stearic acid, Sterotex Registered, talc, waxes, and Stearowet Registered. In a particular embodiment of the invention, the ethylcellulose KCI microcapsules coated with a plasticized polymer coating solution are blended with a diluent, preferably microcrystallme cellulose, optionally a disintegrant and/or a lubricant, and compressed into capsule shaped tablets. In one embodiment, a disintegrant such as crosslinked PVP (Crospovidone) or sodium starch glycolate at a level of 0.2 to 2% w/w and/or a lubricant/surfactant such as sodium lauryl sulfate is optionally blended with the compression mix. In the course of these investigations, it was discovered that sodium lauryl sulfate, widely used as a surfactant produce strong tablets with low friability. It was also discovered that microcapsules fluid bed coated with the plasticized polymeric systems discussed in this patent application could be compressed into strong tablets with low friability without a lubricant (magnesium stearate) or a surfactant (sodium lauryl sulfate). The final tablets will contain a pharmaceutically acceptable amount of potassium chloride. Acceptable daily dosages may be found in The Physicians' Desk Reference, 45th ed. (1991), e.g., 20-200 mEq/day thereof, preferably from about 8 mEq to about 20 mEq. The pharmaceutically elegant 20 mEq Microcaps KCI tablets will exhibit sustained release properties (releasing not more than 40% in one hr and not less than 80% over 8 hrs when tested in USP Apparatus 2 (Paddles @ 50 rpm) in purified water, thereby providing treatments for potassium deficiency in humans with minimal adverse side effects. Typical formulations are given in Example 1-3. Unless otherwise indicated all parts are by weight. Ingredients Example 1 Example 2 Example 3 Film Coating Microcaps KCI 1714.3 1714.3 1714.3 HPMC E5 6.2 30.8 31.5 PEG 400 2.6 13.2 1/1PEG 400/PEG 4000 3.5 Compression Mix Film coated KCI 1723.1 1758.3 1749.3 Microcryst. Cellulose 186.2 200.9 174.9 Crosslinked PVP 39.2 19.9 Sod. Lauryl sulfate 9.8 9.9 Total Tablet weight 1960.2 1989.0 1943.2 Example 1 Microcaps KCI granules (KCI crystals microencapsulated in ethylcellulose) with a 87.5 KCI content were coated with an aqueous solution of hydroxypropylmethyl cellulose (HPMC) and polyethylene glycol 400 (PEG 400) at a ratio of 77/23 to achieve a weight gain of 0.5% w/w. The film coated granules were blended with microcrystalline cellulose (MCC), crosslinked PVP and sodium lauryl sulfate in an amounts of at 9.5%, 2.0% and 0.5% w/w, respectively and compressed into tablets weighing 1960 mg on a rotary tablet press. These tablets containing 1500 mg of Microcaps KCI release slowly over a period of 10 hrs when dissolved in 0.1N HC1 using USP Apparatus 2. Example 2 Microcaps KCI granules (KCI crystals microencapsulated in ethylcellulose) with a 87.5 KCI content were coated to achieve a weight gain of 2.5% w/w with an aqueous solution of HPMC and PEG 400 at a ratio of 77/23. The film coated granules were blended with microcrystalline cellulose and crosslinked PVP at 10.0 and 1.0% w/w, respectively and compressed into tablets weighing 1989 mg on a rotary tablet press. These tablets containing 1500 mg active as Microcaps KCI release slowly over a period of 10 hrs when dissoluted in 0.1N HCL using USP Apparatus 2. Example 3 Microcaps KCI granules (KCI crystals microencapsulated in ethylcellulose) with a 87.5 KCI content were coated with an aqueous solution of HPMC and PEG 400 at a ratio of 77/23 to achieve a weight gain of 1.0% w/w. The film coated granules were blended with microcrystalline cellulose, crosslinked PVP and magnesium stearate at 9.5%, 2.0 and 0.5% w/w, respectively and compressed into tablets weighing 1968 mg on a rotary tablet press. These pharmaceutically elegant tablets containing 1500 mg active as Microcaps KCI release slowly over a period of 10 hrs when dissoluted in 0.1 N HC1 using USP Apparatus 2. Ingredients Example 4 Example 5 Example 6 Film Coating Microcaps KCI 1714.3 1714.3 1714.3 PVP (K-30) 31.5 31.5 1/lEthocel/PVP 31.5 1/1 PEG 400/PEG 4000 3.5 Tri-ethyl citrate 3.5 Dibutyl sebacate 3.5 Compression Mix Film coated KCI 1749.3 1749.3 1749.3 Microcryst. Cellulose 194.4 196.6 194.3 Crosslinked PVP 19.6 Total Tablet weight 1943.7 1965.5 1943.7 Example 4 Microcaps KCI granules (KCI crystals microencapsulated in ethylcellulose) with a 87.5 KCI content were coated with an aqueous solution of polyvinylpyrrolidone (PVP K-30) containing 1 :1 PEG 400/PEG 4000 at 10% w/w to achieve a weight gain of 2.0% w/w. The film coated granules were blended with microcrystalline cellulose at 10.0% w/w and compressed into tablets weighing 1944 mg on a rotary tablet press. These tablets containing 1500 mg active as Microcaps KCI release slowly over a period of 10 hrs when dissoluted in 0.1N HC1 using USP Apparatus 2. Example 5 Microcaps KCI granules (KCI crystals microencapsulated in ethylcellulose) with a 87.5 KCI content were coated to achieve a weight gain of 2.0% w/w with an aqueous solution of PVP and tri-ethyl citrate at a ratio of 97/03. The film coated granules were blended with microcrystalline cellulose and crosslinked PVP at 10.0 and 1.0% w/w, respectively and compressed into tablets weighing 1965 mg on a rotary tablet press. These tablets containing 1500 mg active as Microcaps KCI release slowly over a period of 10 hrs when dissoluted in 0.1N HC1 using USP Apparatus 2. Example 6 Microcaps KCI granules (KCI crystals microencapsulated in ethylcellulose) with a 87.5 KCI content were coated with an IP A/acetone solution of PVP/Ethocel/DBS at a ratio of 48/48/04 to achieve a weight gain of about 2.0% w/w. The film coated granules were blended with microcrystalline cellulose at 10% w/w and compressed into tablets weighing 1944 mg on a rotary tablet press. These pharmaceutically elegant tablets containing 1500 mg active as Microcaps KCI release slowly over a period of 10 hrs when dissoluted in 0.1N HC1 using USP Apparatus 2. The above examples are provided to show how to practice the present invention and are not intended to be exhaustive or to include all obvious modifications and variations which will become apparent to those skilled in formulation development. However, all these modifications are within the scope of the present invention and by the following claims: What is claimed is:

Claims: 1. A process for preparing a controlled release potassium chloride tablet comprising coating potassium chloride crystals with a first coating of a water insoluble polymeric membrane and a second coating of a plasticized hydrophilic polymer, blending the coated potassium chloride crystals with one or more excipients, and compressing the blend into a tablet. 2. The process of claim 1 wherein the water insoluble polymeric membrane contains ethyl cellulose. 3. The process of claim 2 wherein the step of coating the ethylcellulose membrane includes coacervating said ethylcellulose from a solvent in the presence of polyethylene as the phase inducer. 4. The process of claim 2 wherein the primary ethylcellulose membrane has a viscosity of about 90 to 110 cps and is applied to the crystal in an amount of about 8 and about 19% by weight based on the weight of the potassium chloride crystal. 5. The process of claim 4 wherein the hydrophilic polymer membrane is comprised of a water swellable/water soluble polymer selected from the group consisting of acacia, alginic acid or its salt, corn starch, gelatin, xanthan gum, polyvinylpyrrolidone, sodium carboxymethylcellulose, methylcellulose, ethylcellulose having a viscosity from about 4 to 20 cps and hydroxypropylmethyl cellulose or a combination fherofi 6. The process of claim 5 wherein the hydrophilic polymer membrane comprises between about 1 and 4% based on the weight of the ethylcellulose coated crystals. 7. The process of claim 6 wherein the hydrophilic polymeric membrane is formed from a polymer selected from the group consisting of polyvinylpyrrolidone, ethylcellulose and hydroxypropylmethyl cellulose, and mixtures thereof 8. The process of claim 7 wherein the hydrophilic polymeric membrane is plasticized with a compound selected from the group consisting of polyethylene glycols, propylene glycol, triethyl citrate, triacetin, dibutyl phthalate and dibutyl sebacate. 9. The process of claim 8 wherein the hydrophilic polymeric membrane is provided by coating the ethylcellulose coated potassium chloride with an aqueous solution containing about 93 parts by weight PVP and about 7 parts by weight PEG 400 and PEG 4000 (weight ratio 1 : 1 ) for a weight gain of about 2% w/w. 10. The process of claim 8 wherein the hydrophilic polymeric membrane is provided by coating with an aqueous solution containing PVP and dibutyl sebacate at a ratio of 97 parts by weight to 3 parts by weight. 1 1. The process of claim 8 wherein the hydrophilic polymeric membrane is provided by coating with an aqueous solution containing HPMC and PEG 400 at a ratio of 93 parts by weight to 7 parts by weight. 12. The process of claim 8 wherein the hydrophilic polymeric membrane is provided by coating with a solution of ethylcellulose, PVP and dibutyl sebacate at a ratio of about 40 to 48 parts by weight ethylcellulose, about 40 to 48 parts PVP and about 2 to 6 parts dibutyl sebacate. 13. The process of claim 1 wherein the excipient is microcrystalline cellulose or hydrous or anhydrous lactose and the excipient is present in an amount of about 5-15% w/w. 14. The process of claim 13 wherein the excipient additionally includes a disintegrant and a lubricant/surfactant. 15. A potassium chloride tablet comprising a compressed mixture of an excipient and potassium chloride crystals, said crystals being coated with a first layer of a water insoluble polymer and a second layer of a plasticized hydrophilic membrane. 16. The tablet of claim 15 wherein potassium chloride is present in an amount effective for the treatment for potassium deficiency in humans. 17. The tablet of claim 16 wherein the amount of potassium chloride is from about 8 mEq to about 20 mEq. 18. The tablet of claim 15 wherein the tablet releases not more than 40% of the potassium chloride they contain in one hr and not less than 80% of the potassium chloride over a period of 8 hrs when tested in USP Apparatus 2 (Paddles @ 50 rpm) in purified water.

Inventors: GANTT MELISSA, VENKATESH GOPI M, VISHNUPAD KRISHNA S, GANTT, MELISSA, VENKATESH, GOPI, M., VISHNUPAD, KRISHNA, S.
Applicants: EURAND AMERICA INC, EURAND AMERICA, INC.
Application year: 2000
Main classification: A61K9
IPC codes: A61K9, A61K33